In light of today’s announcement regarding the MHRA’s decision to grant a temporary authorisation to supply in response to public health need for the COVID-19 mRNA vaccine (BNT162b2) against SAR-CoV-2, we invited journalists to join a one-hour background briefing with Pfizer UK to learn more about the development of the vaccine, the Phase 3 clinical trial programme and the science behind the mRNA technology.
The journalists dialled in to this briefing to hear from representatives from Pfizer’s UK and European vaccine and medical teams.
Ben Osborn, Country Manager, Pfizer UK
Dr Berkeley Phillips, Medical Director, Pfizer UK
Prof Ralf Rene Reinert, Professor of Microbiology and Infectious Diseases, Vice President, Regional Lead Medical and Scientific Affairs, Pfizer Vaccines
This Briefing was accompanied by an SMC Roundup of Comments.